Small molecule · Inhibitor of HMG-CoA reductase (HMGCR) · developed by Bristol Myers Squibb
ApprovedFDA, Oct 1991
1Registered trials
What is Pravastatin?
Pravastatin is a synthetic lipid-lowering agent that competitively inhibits hepatic HMG-CoA reductase, the enzyme converting HMG-CoA to mevalonate in cholesterol synthesis. It is studied in rheumatoid arthritis.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Pravachol
Drug type
Small molecule
Targets
HMG-CoA reductase (HMGCR)
Mechanism
Inhibitor of HMG-CoA reductase (HMGCR)
Pathways
cholesterol synthesis, mevalonate pathway, MHC II suppression on interferon gamma-stimulated antigen-presenting cells
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.